Lao Tzu
New member
There is a new drug in phase 2 trials called Qnexa, which is just a combination of the off patent drugs phentermine & topamax. They've found that combining the 2 drugs results in far more weight loss than either alone (both are used on and off label as obesity treatments).
http://www.medicalnewstoday.com/medicalnews.php?newsid=43246
Qnexa treatment group experienced 10% or more total body weight loss during the 24-week study period. Mean weight loss on an intent-to-treat (ITT) basis in the Qnexa group was 25.1 lbs., compared to 4.8 lbs in the placebo group (p<0.0001). Importantly, the rate of weight loss for patients in the Qnexa group had not plateaued by the end of the study. Qnexa was well-tolerated with a study completion rate of 92% versus a completion rate of 62% for the placebo group
-- Qnexa achieved significantly greater weight loss as compared to placebo and each of the active single-agent control groups. Moreover, the proportion of patients achieving 10% or more total body weight loss with Qnexa was greater than the sum of both active comparator agents.
-- Qnexa achieved a placebo-adjusted weight loss of 20.3 pounds at week 24.
-- Weight loss with Qnexa had not plateaued by 24 weeks as has been observed with other obesity therapeutics in development.
-- Qnexa was well-tolerated as evidenced by the fact that only four patients (8%) dropped out of the Qnexa study arm, versus 19 patients (38%) on placebo.
This looks pretty interesting. Who wants to be a guinea pig and go buy the drugs from mexico and write us all up a 24 week report?
http://www.medicalnewstoday.com/medicalnews.php?newsid=43246
Qnexa treatment group experienced 10% or more total body weight loss during the 24-week study period. Mean weight loss on an intent-to-treat (ITT) basis in the Qnexa group was 25.1 lbs., compared to 4.8 lbs in the placebo group (p<0.0001). Importantly, the rate of weight loss for patients in the Qnexa group had not plateaued by the end of the study. Qnexa was well-tolerated with a study completion rate of 92% versus a completion rate of 62% for the placebo group
-- Qnexa achieved significantly greater weight loss as compared to placebo and each of the active single-agent control groups. Moreover, the proportion of patients achieving 10% or more total body weight loss with Qnexa was greater than the sum of both active comparator agents.
-- Qnexa achieved a placebo-adjusted weight loss of 20.3 pounds at week 24.
-- Weight loss with Qnexa had not plateaued by 24 weeks as has been observed with other obesity therapeutics in development.
-- Qnexa was well-tolerated as evidenced by the fact that only four patients (8%) dropped out of the Qnexa study arm, versus 19 patients (38%) on placebo.
This looks pretty interesting. Who wants to be a guinea pig and go buy the drugs from mexico and write us all up a 24 week report?